Skip to main content
OpenTrials
Completed

NCT Number: NCT01707472

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

NIH Department of Laboratory Medicine

Bethesda, Maryland, 20892, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • HIV-infected individuals must have positive serologies with viral load suppressed below 400 copies/mL
  • HCV-infected individuals must have:
  • Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:
  • Been null responder to previous pegylated interferon and ribavirin therapy OR
  • Failed to achieve sustained virologic response (SVR) on a regimen containing a direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin OR
  • Are unwilling to receive or have contraindications to interferon therapy for HCV
  • HIV/HCV co-infected individuals must have:
  • Positive HIV serologies with viral load suppressed below 400 copies/mL
  • Chronic HCV infection with HCV RNA ≥ 2000 IU/ml AND at least 1 of the following:
  • Been null responder to previous pegylated interferon and ribavirin therapy OR
  • Failed to achieve SVR on a regimen containing a direct-acting antiviral (DAA) in addition to pegylated interferon and ribavirin OR
  • Are unwilling to receive or have contraindications to interferon therapy for HCV
  • Willing to allow blood and tissue samples to be stored for future use to study HIV infection, immune function, liver disease and additional mechanisms involved in liver fibrosis among patients with HIV and/or HCV, which may not be related directly to the specific objectives of this study protocol
  • Have a primary care physician

Key Exclusion Criteria:

  • Cause of liver fibrosis other than HCV or long-term antiretroviral therapy (ART) treatment for HIV
  • Currently being treated for HCV
  • Evidence of active Hepatitis A, B or D infections
  • History or evidence of hepatocellular carcinoma
  • Unwillingness to undergo a liver biopsy pre-treatment and post-treatment, or to undergo all other protocol required tests/procedures or return to the site for required visits
  • Presence of contraindications to magnetic resonance imaging (e.g., presence of any metal in the body, cardiac or neural pacemaker, aneurysm clip, cochlear implant, claustrophobia)

Treatment and study plan

Simtuzumab

Biological

700 mg intravenously for a total of 12 infusions.

Other names: Anti-LOXL2 Monoclonal Antibody, GS-6624

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: First dose date up to Week 24 plus 30 days

Secondary outcomes

  1. Number of Participants With a Change From Baseline in Ishak Fibrosis Stage Score at Week 24

    Time frame: Baseline; Week 24

    The Ishak fibrosis score measures the degree of liver fibrosis (scarring) and ranges from 0 (best) to 6 (worst). A negative value in change from baseline indicates an improvement and a positive value indicates worsening.

  2. Change From Baseline in HVPG at Week 24

    Time frame: Baseline; Week 24

  3. Change From Baseline in MQC at Week 24

    Time frame: Baseline; Week 24

  4. Change From Baseline in Alpha SMA at Week 24

    Time frame: Baseline; Week 24

  5. Change From Baseline in Liver Fibrosis as Estimated by MRE at Week 24

    Time frame: Baseline; Week 24

Sponsors and collaborators

Lead sponsor

Gilead Sciences

Industry

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Oct 16, 2012
Registry last updated
Nov 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.